Related Experiment Video
Updated: Oct 14, 2025

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
The design of a Bayesian adaptive clinical trial of tranexamic acid in severely injured children
John M VanBuren1, T Charles Casper2, Daniel K Nishijima3
1Department of Pediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA. john.vanburen@hsc.utah.edu.
Insights
This study proposes a Bayesian adaptive trial to find the optimal dose of tranexamic acid (TXA) for children with severe bleeding. This research aims to reduce death and disability from pediatric trauma.
Area of Science:
- Pediatric Emergency Medicine
- Trauma Surgery
- Clinical Trial Design
Background:
- Trauma is a leading cause of death and disability in US children.
- Tranexamic acid (TXA) is known to reduce transfusion needs in adults and children undergoing surgery.
- No randomized controlled trials have investigated TXA's efficacy in pediatric trauma patients.
Purpose of the Study:
- To design and propose a Bayesian adaptive clinical trial to investigate the optimal dose of TXA in children with brain and/or torso hemorrhagic trauma.
- To evaluate the safety and efficacy of different TXA doses in pediatric trauma patients.
- To reduce mortality and morbidity associated with pediatric hemorrhagic trauma.
Main Methods:
- A double-blind, Bayesian adaptive clinical trial enrolling up to 2000 pediatric patients.
- Evaluation of three TXA doses (15, 30, 45 mg/kg bolus) versus placebo using an extended Emax dose-response model.
- Response-adaptive randomization across three injury populations (head, torso, or both) to identify optimal dosing for each group.
Main Results:
- The trial design allows for robust statistical evaluation of TXA efficacy across different pediatric injury types.
- Extensive simulations confirm adequate power to detect treatment effects within each injury group.
- Interim stopping rules are incorporated for efficacy and futility assessments.
Conclusions:
- This innovative trial framework enables simultaneous analysis of TXA efficacy in distinct pediatric injury populations.
- Individualized optimal TXA dosing can be determined for each injury group.
- Identifying optimal TXA doses for pediatric trauma has the potential to significantly decrease childhood death and disability.
Background:
Trauma is the leading cause of death and disability in children in the USA. Tranexamic acid (TXA) reduces the blood transfusion requirements in adults and children during surgery. Several studies have evaluated TXA in adults with hemorrhagic trauma, but no randomized controlled trials have occurred in children with trauma. We propose a Bayesian adaptive clinical trial to investigate TXA in children with brain and/or torso hemorrhagic trauma.
Methods/Design:
We designed a double-blind, Bayesian adaptive clinical trial that will enroll up to 2000 patients. We extend the traditional Emax dose-response model to incorporate a hierarchical structure so multiple doses of TXA can be evaluated in different injury populations (isolated head injury, isolated torso injury, or both head and torso injury). Up to 3 doses of TXA (15 mg/kg, 30 mg/kg, and 45 mg/kg bolus doses) will be compared to placebo. Equal allocation between placebo, 15 mg/kg, and 30 mg/kg will be used for an initial period within each injury group. Depending on the dose-response curve, the 45 mg/kg arm may open in an injury group if there is a trend towards increasing efficacy based on the observed relationship using the data from the lower doses. Response-adaptive randomization allows each injury group to differ in allocation proportions of TXA so an optimal dose can be identified for each injury group. Frequent interim stopping periods are included to evaluate efficacy and futility. The statistical design is evaluated through extensive simulations to determine the operating characteristics in several plausible scenarios. This trial achieves adequate power in each injury group.
Discussion:
This trial design evaluating TXA in pediatric hemorrhagic trauma allows for three separate injury populations to be analyzed and compared within a single study framework. Individual conclusions regarding optimal dosing of TXA can be made within each injury group. Identifying the optimal dose of TXA, if any, for various injury types in childhood may reduce death and disability.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

